Navigation Links
CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
Date:8/20/2009

WHAT: A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

WHEN: The TCT Featured Clinical Trials will be presented on September 24, 2009 from 2:00 6:00 pm.

Session I. Drug-Eluting Stents

  • ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents
    Cheol Whan Lee, MD
  • CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation
    Flavio L Ribichini, MD
  • STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina
    Josef Veselka, MD, PhD
  • NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Randomized Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
    John A. Spertus, MD
  • CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel
    Cheol Whan Lee, MD
  • BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
    Eberhard Grube, MD

Session II. ACS Therapies and Novel Imaging Approaches

  • MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI
    Patrick Ohlmann, MD, PhD
  • COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT Francesco Prati, MD
  • NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI
    Junbo Ge, MD
  • OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT
    Giulio Guagliumi, MD

Session III. End-Stage, Structural Heart and Endovascular Intervention

  • The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis
    Josep Rodes-Cabau, MD
  • CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
    David E. Allie, MD
  • ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
    Gary M. Ansel, MD
  • PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
    Dirk H. Walter, MD
  • ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
    Douglas W. Losordo, MD

WHERE: The Moscone Center San Francisco, CA


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. ESCO Announces Major Contract Award for Its Thermoforming Business
2. CSC Announces Agreement to Provide Billing Service to Colorado West Dermatology
3. Florida Spine Surgeon Alfred Bonati, M.D. Announces Results of National Poll Showing America's Doctors Oppose a Government-Run Health Care Plan
4. AMDL Inc. Announces Second Quarter 2009 Financial Results
5. Chindex International, Inc. Announces New CDC Contract
6. Anthem Blue Cross and Blue Shield in Maine Announces Decision to Cover H1N1 Vaccine Administration
7. Expresso Fitness(R) Announces $6M Series D Funding
8. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
9. Anthem Blue Cross and Blue Shield in New Hampshire Announces Decision to Cover H1N1 Vaccine Administration
10. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
11. American Council on Exercise (ACE) Announces Top Ten Tips to Avoid the Freshman 15
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Steven Tonkinson, ... he has completed every year since it started in 2003. This year, he ran ... attention of fellow runners and NBA team the Miami Heat. , This Sunday, while ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... George H. Van Allen have signed a joint enrollment and degree completion agreement. ... pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows ...
(Date:2/5/2016)... ... 2016 , ... US Sports Camps , official operators of Nike Yoga ... kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New England ... Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
(Date:2/4/2016)... 2016 In response to the opioid abuse epidemic, ... for Medical Products and Tobacco, along with other FDA leaders, ... approach to opioid medications. The plan will focus on policies ... pain access to effective relief. --> ... Re-examine the risk-benefit paradigm for opioids and ensure that the ...
Breaking Medicine Technology: